This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Bio-Rad Laboratories (BIO) Gets a Buy from RBC Capital
RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories today and set a price target of $437.00. The company’s shares closed today at $290.71.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, McNamara is an analyst with an average return of -15.7% and a 28.37% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Hologic, Bio-Rad Laboratories, and Danaher.
Bio-Rad Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $338.25, representing a 16.35% upside. In a report released on August 27, UBS also reiterated a Buy rating on the stock with a $325.00 price target.
BIO market cap is currently $8.06B and has a P/E ratio of 25.39.
Read More on BIO:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
